FibroGen Appoints David DeLucia as Chief Financial Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall St set to open lower as chip rout extends; Netflix slides
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Goldman sees central bank demand providing a floor for gold prices
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
H.C. Wainwright Starts FibroGen (FGEN) at Buy
December 17, 2024 7:57 AM ESTH.C. Wainwright analyst Matt Keller initiates coverage on FibroGen (NASDAQ: FGEN) with a Buy rating and a price target of $10.00.
The analyst comments "FibroGen's ADC pipeline could be a whole new ball game in mCRPC and beyond. We are initiating coverage of FibroGen with a Buy rating and $10 PT. FibroGens lead asset, FG-3246, is a novel antibody drug conjugate (ADC) targeting CD46 expressing tumors.... More
